Thromboxane A2 and Osteoarthritis

Centre Hospitalier Universitaire de Nice

Status: Enrolling

Conditions: Osteoarthritis

Treatments: Other: biological samples

Study type: Observational

Funder types: Other

Identifiers

NCT05593640

22Rhumato03

Details and patient eligibility

About

TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.

Enrollment: 20 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• presence of knee osteoarthritis with effusion, , no inflammatory disease

Exclusion criteria

• anticoagulant treatment
• inflammatory disease

Trial design

20 participants in 1 patient group

ThroboxaneOA

Description:

Patient with osteoarthritis and knee effusion

Treatment:

Other: biological samples